Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients
作者： Bin Wang , Qing Yin , Yu-Chen Han , Min Wu , Zuo-Lin Li
DOI: 10.1080/0886022X.2020.1811121
关键词: Medicine 、 Subgroup analysis 、 Dialysis 、 Cochrane Library 、 Placebo 、 Randomized controlled trial 、 Kidney disease 、 Anemia 、 Internal medicine 、 Adverse effect
摘要: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are orally active first-in-class new generation drugs for renal anemia. This extensive meta-analysis of randomized controlled trials (RCTs) was designed to provide clear information on the efficacy and safety of HIF-PHIs on anemia in chronic kidney disease (CKD) patients. Searches included PubMed, Web of Science, Ovid MEDLINE, and Cochrane Library database up to October 2019. RCTs of patients with CKD comparing HIF-PHIs with erythropoiesis-stimulating agents …
scilit.net参考文章(52)
Mark J. Koury, Volker H. Haase, Anaemia in kidney disease: harnessing hypoxia responses for therapy Nature Reviews Nephrology. ,vol. 11, pp. 394- 410 ,(2015) , 10.1038/NRNEPH.2015.82
Francesco Locatelli, Allen R Nissenson, Brendan J Barrett, Rowan G Walker, David C Wheeler, Kai U Eckardt, Norbert H Lameire, Garabed Eknoyan, None, Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney International. ,vol. 74, pp. 1237- 1240 ,(2008) , 10.1038/KI.2008.299
Toto R Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, TREAT Investigators.., None, A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease The New England Journal of Medicine. ,vol. 361, pp. 2019- 2032 ,(2009) , 10.1056/NEJMOA0907845
Qingdu Liu, Olena Davidoff, Knut Niss, Volker H. Haase, Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis Journal of Clinical Investigation. ,vol. 122, pp. 4635- 4644 ,(2012) , 10.1172/JCI63924
Lynda A Szczech, Huiman X Barnhart, Jula K Inrig, Donal N Reddan, Shelly Sapp, Robert M Califf, Uptal D Patel, Ajay K Singh, None, Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes Kidney International. ,vol. 74, pp. 791- 798 ,(2008) , 10.1038/KI.2008.295
Sophie Vaulont, Lydie Viatte, Isabelle Devaux, Carole Beaumont, Axel Kahn, Gaël Nicolas, Caroline Chauvet, Jean Louis Danan, Xavier Bigard, The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation Journal of Clinical Investigation. ,vol. 110, pp. 1037- 1044 ,(2002) , 10.1172/JCI15686
Nataliya Volkova, Lenore Arab, Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. American Journal of Kidney Diseases. ,vol. 47, pp. 24- 36 ,(2006) , 10.1053/J.AJKD.2005.09.007
Ajay K Singh, Lynda Szczech, Kezhen L Tang, Huiman Barnhart, Shelly Sapp, Marsha Wolfson, Donal Reddan, None, Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease The New England Journal of Medicine. ,vol. 355, pp. 2085- 2098 ,(2006) , 10.1056/NEJMOA065485
Scott D Solomon, Hajime Uno, Eldrin F Lewis, Kai-Uwe Eckardt, Julie Lin, Emmanuel A Burdmann, Dick De Zeeuw, Peter Ivanovich, Andrew S Levey, Patrick Parfrey, Giuseppe Remuzzi, Ajay K Singh, Robert Toto, Fannie Huang, Jerome Rossert, John JV McMurray, Marc A Pfeffer, None, Erythropoietic response and outcomes in kidney disease and type 2 diabetes The New England Journal of Medicine. ,vol. 363, pp. 1146- 1155 ,(2010) , 10.1056/NEJMOA1005109
Shuling Li, Robert N. Foley, Allan J. Collins, Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. International Urology and Nephrology. ,vol. 37, pp. 395- 402 ,(2005) , 10.1007/S11255-004-3068-2